Tamiflu 75 MG capsule 10S
Ended Awarded Last action
- Contract number
- SPE2DR26FCFN3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,013
Award facts
- Contract value 100% obligated
- $11,013.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $11,013 to DMS Pharmaceutical Group Inc. for 10-count packages of Tamiflu 75 mg capsules on December 23, 2025, with completion due by December 24, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without any set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The award carries firm fixed-price terms and does not involve subcontractor relationships.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated SPE2DR, which was awarded on November 13, 2025, with a $499.999 billion ceiling and completion date of December 31, 2036. The PPV-G GEN V represents a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supplying comprehensive pharmaceutical products—including branded and generic prescription drugs, biologics, and medical consumables—to support Department of Defense military healthcare facilities worldwide. The underlying IDC structure with its 30-month base period and three 30-month option periods positions DMS Pharmaceutical Group as a critical pharmaceutical supplier for DoD healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCFN3?
SPE2DR26FCFN3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 23, 2025.
How much is contract SPE2DR26FCFN3 worth?
The government has obligated $11,013 on SPE2DR26FCFN3.
Is contract SPE2DR26FCFN3 an order under another contract?
Yes. SPE2DR26FCFN3 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFN3 competed?
The extent of competition for SPE2DR26FCFN3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award